Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Life Sciences Index Present Pharma Integrates 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Strategically transforming Pharma business relationships.

•    Pharma Integrates 2013 will be held on Tuesday 26th and Wednesday 27th November at the Riverbank Park Plaza, London. Further details available at

•    Following the success of the inaugural Pharma Integrates 2012, PI 2013 will retain the one and a half day conference format. Chairman Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals will be opening the half day series of keynotes and plenary panel discussions. The second day will include multiple tracks, with the majority of the sessions being interactive panel discussions to stimulate information exchange and organic discussion.

•    The overarching theme of Pharma Integrates is ‘Strategically transforming Pharma business relationships’,  with presentations and panel discussions addressing key industry issues from both an early and late product life cycle perspective. In 2013, we will examine how strategic relationships are evolving and increasingly becoming a source of mutual competitive advantage. Further how such collaborations are supporting innovation, productivity, differentiation and profitable growth. Topics to be addressed will include Risk Sharing, Biosimilars, Pricing, Partnering, Open Innovation and Pharma Intellectual Property.

•    Further details of Day One and Day Two Agenda available here:

What to expect from Pharma Integrates 2013

•    Unique panel discussion format ensuring the ultimate interactive experience.

•    Blockbuster topics that straddle a complementary profile of industry stakeholders.

•    Strategically led content dedicated to senior level strategists

•    Unrivalled networking opportunities with champagne reception, luncheon and extended breaks throughout the conference timetable.

Attendee Feedback from Pharma Integrates 2012

“Relevant, good speakers, right size. Made many new contacts – thanks!” Neil Baker, Pfizer.

“Nothing similar in the EU. Panel discussion approach very successful.” Laura Walsh, 3M.

“The event attracted high level delegates and decision makers and was very informal. Good presentations, very entertaining.” Heather Brunyee, Wockhardt.

“Enjoyed the level of attendees, good mix of stakeholders- all with a passion to improve the industry. We now need to deliver!” David Tudbury, Catalent.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos